PubMed Health⌕ Search

PubMed · 10980087

A digital 3-dimensional method for computing great artery flows: in vitro validation studies.

Abstract

BACKGROUND: Conventional 2-dimensional Doppler large vessels are prone to inaccuracy. Three-dimensional (3D) volume imaging provides the opportunity to make cross-sectional flow calculations through digital spatiotemporal integration of flow velocity, area, and profile. METHODS: A new digital 3D color Doppler reconstruction method was used to generate radially acquired flow data sets. Raw scanline data with digital velocity assignments, obtained by scanning parallel to flow, were transferred from a specially programmed but otherwise conventional ultrasonographic system, which controlled a multiplane transesophageal probe, to a computer workstation via an Ethernet link for assimilation into color 3D data sets. This configuration was used to study 20 pulsatile laminar flows (stroke volumes 30 to 70 mL and peak flow rates 65 to 205 mL/s) in a curved tube model with an oval cross-sectional geometry. After generation of the color 3D data set, flow velocity values from cross sections perpendicular to the tubes were analyzed to determine flow rate and stroke volume. RESULTS: The flows from 3D digital velocity profiles showed close correlation with peak instantaneous flow rates (r = 0.99, y = 1.01x-0.9, standard error of estimate 4.1 mL/s). When interpreted with pulsed wave Doppler data obtained through the cardiac cycle, they also allowed computation of stroke volume (r = 0.98, y = 1.44x-2.5, standard error of estimate 3.8 mL). CONCLUSION: The ability to compute laminar flows from 3D digital data sets obtained parallel to the direction of flow and without the need for geometric assumptions represents an important opportunity for and advantage of 3D color Doppler echocardiography.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Irvine, X N Li, Y Mori, S Wanitkun, X Li, P R Detmer, R W Martin, A Pope, G A Schwartz, R A Rusk, A Kenny, D J Sahn. 2000. A digital 3-dimensional method for computing great artery flows: in vitro validation studies.. https://doi.org/10.1067/mje.2000.106049

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Dilated coronary sinus in prenatal echocardiography; identification, associations and outcome.

The dilated coronary sinus (DCS) has only recently been clearly visualised in the fetus due to progress in prenatal echography. This is a retrospective study of 22 fetuses presenting with DCS revealed by prenatal echography. We report the circumstances leading to the detection of a DCS and the neonatal outcome of these fetuses. The coronary sinus was defined as dilated depending on its visualisation in cross-section from the '4 chamber' view, as well as a pseudo inter-atrial septal defect from a more posterior view. In each case the gestational age, circumstances of detection, associated anomalies and postnatal outcome are reported. The circumstances were: evaluation of a clearly identified DCS in four cases and during detailed fetal echocardiography because of suspected congenital heart disease in 18 cases. Five cases were associated with a cardiac anomaly, three with an extracardiac anomaly, six with both cardiac and extracardiac anomaly and eight were isolated. Postnatal outcome was related to the associated anomaly. In conclusion, it is important that the echography image be correctly interpreted, as a DCS often implies possible associated defects and therefore affects prognosis. When not associated with other anomalies this condition is not considered serious.

Coronary Vessels↗

Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries?

During the last decade, an enormous amount of information has been gathered about the function of the platelet and its impact on percutaneous vascular interventions. With the discovery of the GP IIb/IIIa receptor, which is responsible for platelet aggregation, new drug antagonists have been developed to prevent platelet aggregation that may result in arterial thrombosis or platelet microembolization. These drugs include the three GP IIb/IIIa receptor antagonists approved by the Food and Drug Administration: abciximab (ReoPro), eptifibatide (Integrilin), and tirofiban (Aggrastat). These drugs have been used in several large studies to improve the outcome of coronary interventions and in conjunction with plasminogen activators to accelerate thrombolysis. In addition, because no oral GP IIb/IIIa inhibitor exists, other oral regimens have been developed with use of the thienopyridines, ticlopidine (Ticlid) and clopidogrel (Plavix), in combination with aspirin to prevent platelet aggregation and thrombosis. Because the majority of investigations have been performed in patients undergoing coronary interventions, knowledge of these data is necessary to attempt to translate the use of these antiplatelet drugs to peripheral vascular interventions. The goal of this article is to review the use of these agents in the percutaneous treatment of coronary artery disease and give insight to their potential utility in noncoronary interventions.

Coronary Vessels↗